



SEQUENCE LISTING

<110> Zengen, Inc.

<120> Modified Alpha-MSH Peptides and Derviatives Thereof

<130> 54275.8016.US01

<140> 10/714,343

<141> 2003-11-14

<160> 46

<170> PatentIn version 3.1

<210> 1

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized peptide

<220>

<221> MISC_FEATURE

<222> (7)..(7)

<223> Xaa is Phe or DPhe

<400> 1

His Phe Arg Trp Gly Lys Xaa Val

1

5

<210> 2

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<221> MISC_FEATURE

<222> (2)..(2)

<223> Xaa is Phe or DNal

<220>

<221> MISC_FEATURE

<222> (2)..(2)

<223> Xaa is Phe or DNal

<400> 2

His Xaa Phe Trp Gly Lys Pro Val

1

5

<210> 3
 <211> 8
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized peptide

<220>
 <221> MISC_FEATURE
 <222> (2)..(7)
 <223> Xaa is Phe or DPhe

<220>
 <221> MISC_FEATURE
 <222> (2)..(7)
 <223> Xaa is Phe or DPhe

<400> 3

His Xaa Arg Trp Gly Lys Xaa Val
 1 5

<210> 4
 <211> 8
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized peptide

<220>
 <221> MISC_FEATURE
 <222> (7)..(7)
 <223> Xaa is an amino acid bearing a non-polar fnc group.

<220>
 <221> MISC_FEATURE
 <222> (7)..(7)
 <223> Xaa is an amino acid bearing a non-polar fnc group.

<400> 4

His Phe Arg Trp Gly Lys Xaa Val
 1 5

<210> 5
 <211> 8
 <212> PRT
 <213> Artificial Sequence

<220>
<223> Synthesized peptide

<220>
<221> MISC_FEATURE
<222> (8)..(8)
<223> Xaa is an amino acid other than val having a non-polar functional group or a hydrophobic functional group.

<220>
<221> MISC_FEATURE
<222> (8)..(8)
<223> Xaa is an aa other than val having a non-polar functional group or a hydrophobic functional group.

<400> 5

His Phe Arg Trp Gly Lys Pro Xaa
1 5

<210> 6
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized peptide

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> Xaa is an amino acid, not including Lys, having a non-polar functional group.

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> Xaa is an amino acid, not including Lys, having a non-polar functional group.

<400> 6

His Phe Arg Trp Gly Xaa Pro Val
1 5

<210> 7
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized peptide

<220>
<221> MISC_FEATURE
<222> (7)..(7)
<223> X is an aa with positively charged fuctionnal group.

<220>
<221> MISC_FEATURE
<222> (7)..(7)
<223> Xaa is an amino acid with positively charged fuctionnal group.

<220>
<221> MISC_FEATURE
<222> (7)..(7)
<223> Xaa is an amino acid with positively charged fuctionnal group.

<400> 7

His Phe Arg Trp Gly Lys Xaa Val
1 5

<210> 8
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized peptide

<220>
<221> MISC_FEATURE
<222> (7)..(7)
<223> Xaa is an amino acid having a negatively charged functional group.

<220>
<221> MISC_FEATURE
<222> (7)..(7)
<223> Xaa is an amino acid having a negatively charged functional group

<400> 8

His Phe Arg Trp Gly Lys Xaa Val
1 5

<210> 9
<211> 8

<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized peptide

<220>
<221> MISC_FEATURE
<222> (2)..(7)
<223> Xaa at 2 is DPhe or DNal and Xaa at 7 is an aa having a negatively charged functional group

<220>
<221> MISC_FEATURE
<222> (2)..(7)
<223> Xaa at 2 is DPhe or DNal and X at 7 is an amino acid having a negatively charged functional group

<400> 9

His Xaa Arg Trp Gly Lys Xaa Val
1 5

<210> 10
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized peptide

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> Trp is DTrp

<400> 10

His Phe Arg Trp Gly Lys Pro Val
1 5

<210> 11
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized peptide

<220>
<221> MISC_FEATURE
<222> (7)..(7)

<223> Xaa is an uncharged functional group polar aa.

<220>

<221> MISC_FEATURE

<222> (7)..(7)

<223> Xaa is an uncharged functional group polar aa.

<220>

<221> MISC_FEATURE

<222> (7)..(7)

<223> Xaa is an uncharged functional group polar amino acid.

<400> 11

His Phe Arg Trp Gly Lys Xaa Val

1

5

<210> 12

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized peptide

<220>

<221> MISC_FEATURE

<222> (2)..(7)

<223> Xaa at 2 is DPhe or DNal; Xaa at 7 is an aa with an uncharged polar functional group.

<220>

<221> MISC_FEATURE

<222> (2)..(7)

<223> Xaa at 2 is DPhe or DNal; Xaa at 7 is an amino acid with an uncharged polar functional group.

<400> 12

His Xaa Arg Trp Gly Lys Xaa Val

1

5

<210> 13

<211> 13

<212> PRT

<213> Homo sapiens

<400> 13

Ser Tyr Ser Met Glu His Phe Arg Trp Gly Lys Pro Val

1 5 10

<210> 14
 <211> 39
 <212> PRT
 <213> Homo sapiens

<400> 14

Ser Tyr Ser Met Glu His Phe Arg Trp Gly Lys Pro Val Gly Lys Lys
 1 5 10 15

Arg Arg Pro Val Lys Val Tyr Pro Ala Lys Glu Asp Asp Glu Ala Ser
 20 25 30

Glu Ala Phe Pro Leu Glu Phe
 35

<210> 15
 <211> 7
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized peptide

<220>
 <221> PEPTIDE
 <222> (1)..(7)
 <223>

<400> 15

Met Glu His Phe Arg Trp Gly
 1 5

<210> 16
 <211> 3
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized peptide

<220>
 <221> PEPTIDE
 <222> (1)..(3)
 <223>

<400> 16

Lys Pro Val

1

<210> 17
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized peptide

<220>
<221> PEPTIDE
<222> (1)..(4)
<223>

<400> 17

His Phe Arg Trp

1

<210> 18
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized peptide

<220>
<221> MISC_FEATURE
<222> (8)..(8)
<223> Val is DVal

<400> 18

His Phe Arg Trp Gly Lys Pro Val

1

5

<210> 19
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized peptide

<220>
<221> PEPTIDE
<222> (1)..(8)
<223>

<400> 19

His Phe Arg Trp Gly Ala Pro Val
1 5

<210> 20

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized peptide

<220>

<221> PEPTIDE

<222> (1)..(8)

<223>

<400> 20

His Phe Arg Trp Gly Lys Ala Val
1 5

<210> 21

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized peptide

<220>

<221> PEPTIDE

<222> (1)..(8)

<223>

<400> 21

His Phe Arg Trp Gly Lys Pro Ala
1 5

<210> 22

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized peptide

<220>

<221> MISC_FEATURE
 <222> (2)..(2)
 <223> Phe is DPhe

<400> 22

His Phe Arg Trp Gly Lys Pro Val
 1 5

<210> 23
 <211> 8
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized peptide

<220>
 <221> MISC_FEATURE
 <222> (2)..(2)
 <223> Xaa is DNal

<220>
 <221> MISC_FEATURE
 <222> (2)..(2)
 <223> Xaa is DNal

<400> 23

His Xaa Arg Trp Gly Lys Pro Val
 1 5

<210> 24
 <211> 8
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized peptide

<220>
 <221> MISC_FEATURE
 <222> (4)..(4)
 <223> Trp is DTrp

<400> 24

His Phe Arg Trp Gly Lys Pro Val
 1 5

<210> 25
 <211> 8
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized peptide

<220>
 <221> PEPTIDE
 <222> (1)..(8)
 <223>

<400> 25

His Phe Arg Trp Gly Lys Pro Leu
 1 5

<210> 26
 <211> 8
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized peptide

<220>
 <221> MISC_FEATURE
 <222> (7)..(7)
 <223> Ala is DALa

<400> 26

His Phe Arg Trp Gly Lys Ala Val
 1 5

<210> 27
 <211> 8
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized peptide

<220>
 <221> MISC_FEATURE
 <222> (2)..(2)
 <223> Xaa is DNAl

<220>
 <221> MISC_FEATURE
 <222> (2)..(2)

<223> Xaa is DNal

<400> 27

His Xaa Arg Trp Gly Lys Ala Val
1 5

<210> 28

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized peptide

<220>

<221> MISC_FEATURE

<222> (2)..(7)

<223> Xaa is DNal; Ala is DAla

<220>

<221> MISC_FEATURE

<222> (2)..(7)

<223> Xaa is DNal; Ala is DAla

<400> 28

His Xaa Arg Trp Gly Lys Ala Val
1 5

<210> 29

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized peptide

<220>

<221> PEPTIDE

<222> (1)..(8)

<223>

<400> 29

His Phe Arg Trp Gly Lys Gly Val
1 5

<210> 30

<211> 8

<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized peptide

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa is DNal

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa is DNal

<400> 30

His Xaa Arg Trp Gly Lys Gly Val
1 5

<210> 31
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized peptide

<220>
<221> PEPTIDE
<222> (1)..(8)
<223>

<400> 31

His Phe Arg Trp Gly Lys Ser Val
1 5

<210> 32
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized peptide

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa is DNal

<220>
 <221> MISC_FEATURE
 <222> (2)..(2)
 <223> Xaa is DNal

<400> 32

His Xaa Arg Trp Gly Lys Ser Val
 1 5

<210> 33
 <211> 8
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized peptide

<220>
 <221> PEPTIDE
 <222> (1)..(8)
 <223>

<400> 33

His Phe Arg Trp Gly Lys Phe Val
 1 5

<210> 34
 <211> 8
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized peptide

<220>
 <221> MISC_FEATURE
 <222> (7)..(7)
 <223> Phe is DPhe

<400> 34

His Phe Arg Trp Gly Lys Phe Val
 1 5

<210> 35
 <211> 8
 <212> PRT
 <213> Artificial Sequence

<220>
<223> Synthesized peptide

<220>
<221> MISC_FEATURE
<222> (2)..(7)
<223> Phe is DPhe at 2 and 7

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Phe is DPhe at 2

<400> 35

His Phe Arg Trp Gly Lys Phe Val
1 5

<210> 36
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized peptide

<220>
<221> MISC_FEATURE
<222> (2)..(7)
<223> Phe is DPhe at 2 and 7

<400> 36

His Phe Arg Trp Gly Lys Phe Val
1 5

<210> 37
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized peptide

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> X is DNal

<220>

<221> MISC_FEATURE
 <222> (2)..(2)
 <223> Xaa is DNal

<220>
 <221> MISC_FEATURE
 <222> (2)..(2)
 <223> Xaa is DNal

<400> 37

His Xaa Arg Trp Gly Lys Phe Val
 1 5

<210> 38
 <211> 8
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized peptide

<220>
 <221> MISC_FEATURE
 <222> (2)..(7)
 <223> Xaa is DNal Phe is DPhe at 7

<220>
 <221> MISC_FEATURE
 <222> (2)..(7)
 <223> Xaa is DNal Phe is DPhe at 7

<400> 38

His Xaa Arg Trp Gly Lys Phe Val
 1 5

<210> 39
 <211> 8
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized peptide

<220>
 <221> PEPTIDE
 <222> (1)..(8)
 <223>

<400> 39

His Phe Arg Trp Gly Lys Asp Val
1 5

<210> 40

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized peptide

<220>

<221> MISC_FEATURE

<222> (7)..(7)

<223> Asp is DAsp

<400> 40

His Phe Arg Trp Gly Lys Asp Val
1 5

<210> 41

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized peptide

<220>

<221> MISC_FEATURE

<222> (2)..(2)

<223> Phe at 2 is DPhe

<400> 41

His Phe Arg Trp Gly Lys Asp Val
1 5

<210> 42

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized peptide

<220>

<221> MISC_FEATURE

<222> (2)..(2)

<223> Xaa is DNal

<220>

<221> MISC_FEATURE

<222> (2)..(2)

<223> Xaa is DNal

<400> 42

His Xaa Arg Trp Gly Lys Asp Val
1 5

<210> 43

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized peptide

<220>

<221> PEPTIDE

<222> (1)..(8)

<223>

<400> 43

His Phe Arg Trp Gly Lys Glu Val
1 5

<210> 44

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized peptide

<220>

<221> MISC_FEATURE

<222> (2)..(2)

<223> Xaa is DNal

<220>

<221> MISC_FEATURE

<222> (2)..(2)

<223> Xaa is DNal

<400> 44

His Xaa Arg Trp Gly Lys Glu Val
1 5

<210> 45
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized peptide

<220>
<221> PEPTIDE
<222> (1)..(8)
<223>

<400> 45

His Phe Arg Trp Gly Lys Lys Val
1 5

<210> 46
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized peptide

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa is DNal

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa is DNal

<400> 46

His Xaa Arg Trp Gly Lys Lys Val
1 5